US2003064499A1PendingUtilityA1
Hepatitis C virus protease
Priority: Apr 4, 1990Filed: Jun 18, 2001Published: Apr 3, 2003
Est. expiryApr 4, 2010(expired)· nominal 20-yr term from priority
C07K 2319/02C12N 2770/24222C07K 14/00C07K 2319/95C07K 2319/00C12N 9/0089A61K 38/00C12N 9/506C07K 14/005C12N 9/90
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1 . A composition comprising a purified proteolytic polypeptide derived from Hepatitis C virus.
2 . The composition of claim 1 , wherein said polypeptide has a partial internal sequence substantially as follows:
Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr.
3 . The composition of claim 1 , wherein said polypeptide has a partial internal sequence substantially as follows:
Leu Lys Gly Ser Ser Gly Gly Pro Leu.
4 . The composition of claim 2 , wherein said polypeptide has substantially the partial internal sequence:
Arg Arg Gly Arg Glu Ile Leu Leu Gly Pro Ala Asp Gly Met Val Ser Lys Gly
Trp Arg Leu Leu Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu
Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu
Val Gln Ile Val Ser Thr Ala Ala Gln Thr Phe Leu Ala Thr Cys Ile Asn Gly
Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr Ile Ala Ser Pro Lys
Gly Pro Val Ile Gln Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro
Ala Pro Gln Gly Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu
Tyr Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser Gly
Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu
Thr Thr Met Arg.
5 . The composition of claim 1 , wherein said polypeptide has substantially the amino acid sequence shown in FIG. 1.
6 . A fusion protein, comprising:
a suitable fusion partner, fused to a proteolytic polypeptide derived from Hepatitis C virus.
7 . The fusion protein of claim 6 , wherein said fusion partner comprises human superoxide dismutase.
8 . The fusion protein of claim 6 , wherein said proteolytic polypeptide has a partial internal sequence substantially as follows:
Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr.
9 . The fusion protein of claim 6 , wherein said proteolytic polypeptide has a partial internal sequence substantially as follows:
Leu Lys Gly Ser Ser Gly Gly Pro Leu.
10 . The fusion protein of claim 6 , wherein said proteolytic polypeptide has as a partial internal sequence:
Arg Arg Gly Arg Glu Ile Leu Leu Gly Pro Ala Asp
Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro
Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu
Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys
Asn Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr
Ala Ala Gln Thr Phe Leu Ala Thr Cys Ile Asn Gly
Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg
Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro
Ala Pro Gln Gly Ser Arg Ser Leu Thr Pro Cys Thr
Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr
Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro
Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
Pro Val Glu Asn Leu Glu Thr Thr Met Arg.
11 . The fusion protein of claim 6 , wherein said fusion partner is ubiquitin.
12 . A composition comprising a polynucleotide which encodes only the HCV protease or an active HCV protease analog.
13 . The composition of claim 12 , wherein said polynucleotide encodes the HCV protease of FIG. 1.
14 . A composition comprising a polynucleotide which encodes a fusion protein comprising:
HCV protease or HCV protease analog; and a fusion partner.
15 . The composition of claim 14 , wherein said fusion partner is selected from the group consisting of hSOD, yeast a-factor, IL-2S, ubiquitin, β-galactosidase, β-lactamase, horseradish peroxidase, glucose oxidase, and urease.
16 . The composition of claim 14 , wherein said HCV protease or HCV protease analog comprises a polypeptide having substantially the following sequence:
Arg Arg Gly Arg Glu Ile Leu Leu Gly Pro Ala Asp
Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro
Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu
Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys
Asn Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr
Ala Ala Gln Thr Phe Leu Ala Thr Cys Ile Asn Gly
Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg
Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro
Ala Pro Gln Gly Ser Arg Ser Leu Thr Pro Cys Thr
Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr
Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro
Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
Pro Val Glu Asn Leu Glu Thr Thr Met Arg.
17 . The composition of claim 14 , wherein said HCV protease or analog comprises a polypeptide having substantially the sequence:
Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg
Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val
Ala Val Glu Pro Val Val Phe Ser Gln Met Glu Thr
Lys Leu Ile Thr Trp Gly Ala Asp Thr Ala Ala Cys
Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala Arg
Arg Gly Arg Glu Ile Leu Leu Gly Pro Ala Asp Gly
Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro Ile
Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu Gly
Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn
Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr Ala
Ala Gln Thr Phe Leu Ala Thr Cys Ile Ile Asn Gly
Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg
Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro
Ala Ser Gln Gly Thr Arg Ser Leu Thr Pro Cys Thr
Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr
Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro
Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro
Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro
Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr
Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala.
18 . The composition of claim 14 , wherein said polypeptide has substantially the sequence:
Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg
Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val
Ala Val Glu Pro Val Val Phe Ser Gln Met Glu Thr
Lys Leu Ile Thr Trp Gly Ala Asp Thr Ala Ala Cys
Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala Arg
Arg Gly Arg Glu Ile Leu Leu Gly Pro Ala Asp Gly
Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro Ile
Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu Gly
Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn
Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr Ala
Ala Gln Thr Phe Leu Ala Thr Cys Ile Ile Asn Gly
Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg
Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro
Ala Ser Gln Gly Thr Arg Ser Leu Thr Pro Cys Thr
Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
Ala Asp Val Ile Pro Val Arg.
19 . A method for assaying compounds for activity against hepatitis C virus, comprising:
providing an active hepatitis C virus protease; contacting said protease with a compound capable of inhibiting serine protease activity; and measuring inhibition of the proteolytic activity of said hepatitis C virus protease.
20 . An expression vector for producing HCV protease or HCV protease analogs in a host cell, which vector comprises:
a polynucleotide encoding HCV protease or an HCV analog; transcriptional and translational regulatory sequences functional in said host cell operably linked to said HCV protease-encoding polynucleotide; and a selectable marker.
21 . The vector of claim 20 , which further comprises a sequence encoding a fusion partner, linked to said HCV protease-encoding polynucleotide to form a fusion protein upon expression.
22 . The vector of claim 21 , wherein said fusion partner is selected from the group consisting of hSOD, yeast α-factor, IL-2S, ubiquitin, β-galactosidase, β-lactamase, horseradish peroxidase, glucose oxidase, and urease.
23 . The vector of claim 22 , where in said fusion partner is selected from the group consisting of ubiquitin, hSOD, and yeast α-factor.
24 . The vector of claim 20 , wherein said HCV protease-encoding polynucleotide encodes a polypeptide having the substantially the following sequence:
Arg Arg Gly Arg Glu Ile Leu Leu Gly Pro Ala Asp
Gly Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro
Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu
Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys
Asn Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr
Ala Ala Gln Thr Phe Leu Ala Thr Cys Ile Asn Gly
Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg
Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro
Ala Pro Gln Gly Ser Arg Ser Leu Thr Pro Cys Thr
Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr
Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro
Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
Pro Val Glu Asn Leu Glu Thr Thr Met Arg.
25 . The vector of claim 20 , wherein said HCV protease-encoding polynucleotide encodes a polypeptide having the substantially the following sequence:
Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg
Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val
Ala Val Glu Pro Val Val Phe Ser Gln Met Glu Thr
Lys Leu Ile Thr Trp Gly Ala Asp Thr Ala Ala Cys
Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala Arg
Arg Gly Arg Glu Ile Leu Leu Gly Pro Ala Asp Gly
Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro Ile
Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu Gly
Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn
Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr Ala
Ala Gln Thr Phe Leu Ala Thr Cys Ile Ile Asn Gly
Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg
Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro
Ala Ser Gln Gly Thr Arg Ser Leu Thr Pro Cys Thr
Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
Ala Asp Val Ile Pro Val Arg.
26 . The vector of claim 20 , wherein said HCV protease-encoding polynucleotide encodes a polypeptide having the substantially the following sequence:
Gly Thr Tyr Val Tyr Asn His Leu Thr Pro Leu Arg
Asp Trp Ala His Asn Gly Leu Arg Asp Leu Ala Val
Ala Val Glu Pro Val Val Phe Ser Gln Met Glu Thr
Lys Leu Ile Thr Trp Gly Ala Asp Thr Ala Ala Cys
Gly Asp Ile Ile Asn Gly Leu Pro Val Ser Ala Arg
Arg Gly Arg Glu Ile Leu Leu Gly Pro Ala Asp Gly
Met Val Ser Lys Gly Trp Arg Leu Leu Ala Pro Ile
Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu Gly
Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn
Gln Val Glu Gly Glu Val Gln Ile Val Ser Thr Ala
Ala Gln Thr Phe Leu Ala Thr Cys Ile Ile Asn Gly
Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg
Thr Ile Ala Ser Pro Lys Gly Pro Val Ile Gln Met
Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro
Ala Ser Gln Gly Thr Arg Ser Leu Thr Pro Cys Thr
Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser
Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr
Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro
Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile
Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro
Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro
Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr
Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala.Join the waitlist — get patent alerts
Track US2003064499A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.